# Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

> **NCT07684469** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 300 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** inclisiran
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT07684469
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-02-28
- **Final completion:** 2028-10-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684469, "Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*